A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Authors: Matthew S. Davids, Danielle M. Brander, Yesid Alvarado-Valero, Catherine S. Diefenbach, Daniel N. Egan, Shira N. Dinner, Nathalie Javidi-Sharifi, Monzr M. Al Malki, Kebede H. Begna, Vijaya Raj Bhatt, Sameem Abedin, Rachel J. Cook, Mary C. Collins, Carly Roleder, Edward C. Dominguez, Prabhu Rajagopalan, Sandra E. Wiley, Richard G. Ghalie, Alexey V. Danilov

Source: Blood Advances, Vol 9, Iss 4, Pp 820-832 (2025)

Subject Terms: Specialties of internal medicine, RC581-951

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2473952924007389; https://doaj.org/toc/2473-9529

Access URL: https://doaj.org/article/2aa72875eca04ce4874665f5062ee17f

The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome

Authors: Dominic LaBella, Samuel Regan, Heiko Konig, Daniel N. Egan, Neil A. Bailey, Raya Mawad, Morgan Gilbert, John M. Pagel, Jeffrey J. Pu

Source: Frontiers in Oncology, Vol 12 (2022)

Subject Terms: Acute Promyelocytic Leukemia, All-Trans-Retinoic Acid (ATRA), Arsenic Trioxide (ATO), Differentiation Syndrome (DS), Adjuvant Chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.911745/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/e3a605d3354d45f5be18821ef3ff9bac